Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer disease

NeuroMolecular Medicine

Volumn 9, Issue 2, 2007, Pages 157-168

  Lahiri, Debomoy K ^a   Alley, George M ^a   Tweedie, David ^b   Chen, Demao ^a   Greig, Nigel H ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Acetylcholine; Aging; Anticholinesterase; Cell culture; CNS; Dementia; Drugs; ELISA; Neuron; Phenylcarbamate; protein

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; PHENSERINE; PHYSOSTIGMINE;

ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; NERVE CELL CULTURE; NEUROBLASTOMA CELL; NEUROPATHOLOGY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STRUCTURAL HOMOLOGY;

EID: 34447567415     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02685889     Document Type: Article

References (35)

1. Borroni B., Colciaghi F., Pastorino L., et al. (2001) Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. Arch. Neurol. 58, 442-446.
2. Briones T. L. (2006) Environment, physical activity, and neurogenesis: implications for prevention and treatment of Alzhemier's disease. Curr. Alzheimer Res. 3, 49-54.
3. Cummings J. L. (2003) Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am. J. Geriatr. Psychiatry 11, 131-145.
4. Davis K. L. (1998) Future therapeutic approaches to Alzheimer's disease. J. Clin. Psychiatry 59(Suppl 11), 14-16.
5. DeKosky S. T. (2003) Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J. Am. Geriatr. Soc. 51, S314-S320.
6. Doraiswamy P. M. (2002) Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 16, 811-824.
7. Giacobini E. (2003) Cholinesterases: New roles in brain function and in Alzheimer's disease. Neurochem. Res. 28, 515-522.
8. Greig N. H., Pei X. F., Soncrant T. T., Ingram D. K., and Brossi A. (1995) Phenserine and ring C heteroanalogues: drug candidates for the treatment of Alzheimer's disease. Med. Res. Rev. 15, 3-31.
9. Greig N. H., Sambamurti K., Yu Q. S., Brossi A., Bruinsma G. B., and Lahiri D. K. (2005a) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. 2, 281-290.
10. Greig N. H., De Micheli E., Holloway H. W., et al. (2000) The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol. Scand. Suppl. 176, 74-84.
11. Greig N. H., Utsuki T., Ingram D. K., et al. (2005b) Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. USA 102, 17,213-17,218.
12. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
13. Haroutunian V., Greig N., Pei X. F., et al. (1997) Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res. Mol. Brain Res. 46, 161-168.
14. Jacobsen J. S., Reinhart P., and Pangalos M. N. (2005) Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx. 2, 612-626.
15. Lahiri D. K. and Farlow M. R. (1996) Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J. Mol. Neurosci. 7, 41-49.
16. Lahiri D. K., Farlow M. R., and Sambamurti K. (1998) The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res. Mol. Brain Res. 62, 131-140.
17. Lahiri D. K., Lewis S., and Farlow M. R. (1994) Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J. Neurosci. Res. 37, 777-787.
18. Lahiri D. K., Farlow M. R., Greig N. H., and Sambamurti K. (2002) Current drug targets for Alzheimer's disease treatment. Drug Dev. Res. 56, 267-281.
19. Lahiri D. K., Chen D., Ge Y. W., Bondy S. C., and Sharman E. H. (2004a) Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J. Pineal Res. 36, 224-231.
20. Lahiri D. K., Farlow M. R., Hintz N., Utsuki T., and Greig N. H. (2000) Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol. Scand. Suppl. 176, 60-67.
21. Lahiri D. K., Chen D., Lahiri P., Rogers J. T., Greig N. H., and Bondy S. (2004b) Melatonin, metals, and gene expression: implications in aging and neurodegenerative disorders. Ann. N. Y. Acad. Sci. 1035, 216-230.
22. Lahiri D. K., Chen D., Vivien D., Ge Y. W., Greig N. H., and Rogers J. T. (2003a) Role of cytokines in the gene expression of amyloid beta-protein precursor: Identification of a 5′-UTR-Binding nuclear factor and its implications in Alzheimer's disease. J. Alzheimers Dis. 5, 81-90.
23. Lahiri D. K., Farlow M. R., Sambamurti K., Greig N. H., Giacobini E., and Schneider L. S. (2003b) A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 4, 97-112.
24. Luo W., Yu Q. S., Kulkarni S. S., et al. (2006) Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J. Med. Chem. 49, 2174-2185.
25. Munoz F. J., Aldunate R., and Inestrosa N. C. (1999) Peripheral binding site is involved in the neurotrophic activity of acetylcholinesterase. Neuroreport 10, 3621-3625.
26. Pakaski M. and Kasa P. (2003) Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr. Drug Targets CNS Neurol. Disord. 2, 163-171.
27. Pakaski M., Rakonczay Z., and Kasa P. (2001) Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro. Neurochem. Int. 38, 219-226.
28. Patel N., Spangler E. L., Greig N. H., Yu Q. S., Ingram D. K., and Meyer R. C. (1998) Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. Neuroreport 9, 171-176.
29. Racchi M. and Govoni S. (2003) The pharmacology of amyloid precursor protein processing. Exper. Geront. 38, 145-157.
30. Rogers J. T., Randall J. D., Cahill C. M., et al. (2002) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277, 45,518-45,528.
31. Sambamurti K., Greig N. H., and Lahiri D. K. (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromol. Med. 1, 1-31.
32. Shaw K. T., Utsuki T., Rogers J., et al. (2001) Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA 98, 7605-7610.
33. Thal L. J. (2003) Therapeutics and mild cognitive impairment: current status and future directions. Alzheimer Dis. Assoc. Disord. 17(Suppl 2), 69-71.
34. Utsuki T., Yu Q.-S., Davidson D., et al. (2006) Identification of novel small molecule inhibitors of APP protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J. Pharmacol. Exp. Ther. In press.
35. Yu Q., Holloway H. W., Flippen-Anderson J. L., Hoffman B., Brossi A., and Greig N. H. (2001) Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J. Med. Chem. 44, 4062-4071.